Description
The LANCE® Ultra Human tPA Detection Kit is designed for detection and quantitation of human tPA in cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.
No-wash steps, no separation steps
TR-FRET technology
Sensitive detection
High reproducibility
Faster time-to-results
Easy automation
96-well, 384-well, and 1536-well formats
LANCE® and LANCE® (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight™ dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.
Tissue Plasminogen Activator (tPA) is a 59 kDa secreted serine protease that converts the proenzyme plasminogen to plasmin, a fibrinolytic enzyme. It is synthesized in numerous tissues and is the principal endogenous activator of plasminogen in blood. It plays a role in cell migration and tissue remodeling. Increased enzymatic activity causes hyperfibrinolysis, which manifests as excessive bleeding; decreased activity leads to hypofibrinolysis that can result in thrombosis or embolism. Rapid fluctuations in tPA concentration can be observed in response to exercise, venous occlusion, alcohol, and drugs, such as anabolic steroids. Individuals who do not show increased tPA activity when exposed to some of these stimuli, may be at risk for deep vein thrombosis.
